Edition:
United States

People: AEterna Zentaris Inc (AEZS.O)

AEZS.O on Consolidated Issue listed on NASDAQ Capital Market

3.37USD
29 Jul 2016
Change (% chg)

$0.02 (+0.60%)
Prev Close
$3.35
Open
$3.40
Day's High
$3.40
Day's Low
$3.31
Volume
36,563
Avg. Vol
218,188
52-wk High
$20.76
52-wk Low
$2.60

Dodd, David 

Mr. David A. Dodd is Chairman of the Board, President, Chief Executive Officer of Aeterna Zentaris Inc. Mr. Dodd's executive management experience in the pharmaceutical and biotechnology industries spans more than 35 years. Prior to joining Aeterna Zentaris, Mr. Dodd was President and CEO of Solvay Pharmaceuticals, Inc. During his six-year tenure as President, CEO and Director of Serologicals Corporation, the market value of the company increased from $85 million in June 2000 to an all-cash sale to Millipore Corporation in July 2006 for $1.5 billion. He also was President, CEO and Chairman of BioReliance Corporation, a leading provider of biological safety and related testing services. Prior to that, Mr. Dodd held various senior management positions at Wyeth-Ayerst Laboratories, the Mead Johnson Laboratories Division at Bristol-Myers Squibb, and Abbott Laboratories. Mr. Dodd holds a Master degree from Georgia State University, and completed the Harvard Business School Advanced Management Program.

Basic Compensation

Total Annual Compensation, USD 378,846
Restricted Stock Awards, USD 414,048
Long-Term Incentive Plans, USD --
All Other, USD 486,106
Fiscal Year Total, USD 1,279,000

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --